Cletus Adiyaga Wezena
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Cletus Adiyaga Wezena has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Julius Tieroyaare Dongdem
University for Development Studies
2 shared publications - Augustine Ocloo
Department of Biochemistry, Cell and Molecular Biology, School of Biological Science, University of Ghana, Legon, Accra, P.O. Box LG 25, Ghana
1 shared publication Axandrah E. Etornam
Department of Biochemistry and Molecular Medicine, School of Medicine, University for Development Studies, Tamale, Northern Region, Ghana
1 shared publicationBismarck Dinko
Department of Biomedical Sciences, School of Basic and Biomedical Sciences, University of Health and Allied Sciences, Ho. Ghana
1 shared publicationCletus A. Wezena
Department of Microbiology, Faculty of Bioscience, University for Development Studies, Nyankpala Campus, Tamale, Ghana
1 shared publicationDaniel Abugri
Department of Biological Sciences, Microbiology PhD Programme, Laboratory of Ethnomedicine, Parasitology, and Drug Discovery, College of Science, Technology, Engineering and Mathematics, Alabama State University, Montgomery, USA
1 shared publication
Latest Publications
- Open Access
- 1 January 2024
- Published by Wiley in Advances in Pharmacological and Pharmaceutical Sciences
- Vol. 2024 (1) , 2005589
The β3‐Adrenergic Receptor: Structure, Physiopathology of Disease, and Emerging Therapeutic Potential
The discovery and characterization of the signal cascades of the β‐adrenergic receptors have made it possible to effectively target the receptors for drug development. β‐Adrenergic receptors are a class A rhodopsin type of G protein‐coupled receptors (GPCRs) that are stimulated mainly by catecholamines and therefore mediate diverse effects of the parasympathetic nervous system in eliciting “fight or flight” type responses. They are detectable in several human tissues where they control a plethora of physiological processes and therefore contribute to the pathogenesis of several disease conditions. Given the relevance of the β‐adrenergic receptor as a molecular target for many pathological conditions, this comprehensive review aims at providing an in‐depth exploration of the recent advancements in β3‐adrenergic receptor research. More importantly, we delve into the prospects of the β3‐adrenergic receptor as a therapeutic target across a variety of clinical domains.
- 1 January 2024
- Published by Wiley in Advances in Pharmacological and Pharmaceutical Sciences
- Vol. 2024 (1) , 2005589
Open AccessThe β3‐Adrenergic Receptor: Structure, Physiopathology of Disease, and Emerging Therapeutic Potential
The discovery and characterization of the signal cascades of the β‐adrenergic receptors have made it possible to effectively target the receptors for drug development. β‐Adrenergic receptors are a class A rhodopsin type of G protein‐coupled receptors (GPCRs) that are stimulated mainly by catecholamines and therefore mediate diverse effects of the parasympathetic nervous system in eliciting “fight or flight” type responses. They are detectable in several human tissues where they control a plethora of physiological processes and therefore contribute to the pathogenesis of several disease conditions. Given the relevance of the β‐adrenergic receptor as a molecular target for many pathological conditions, this comprehensive review aims at providing an in‐depth exploration of the recent advancements in β3‐adrenergic receptor research. More importantly, we delve into the prospects of the β3‐adrenergic receptor as a therapeutic target across a variety of clinical domains.
- Open Access
Targeting the Plasmodium falciparum proteome and organelles for potential antimalarial drug candidates
- Open Access
- 4 January 2022
- Published by Springer Nature in BMC Pharmacology and Toxicology
- Vol. 23 (1) , 1-11
Assessment of NSAIDs as potential inhibitors of the fatty acid amide hydrolase I (FAAH-1) using three different primary fatty acid amide substrates in vitro
Pain relief remains a major subject of inadequately met need of patients. Therapeutic agents designed to treat pain and inflammation so far have low to moderate efficiencies with significant untoward side effects. FAAH-1 has been proposed as a promising target for the discovery of drugs to treat pain and inflammation without significant adverse effects. FAAH-1 is the primary enzyme accountable for the degradation of AEA and related fatty acid amides. Studies have revealed that the simultaneous inhibition of COX and FAAH-1 activities produce greater pharmacological efficiency with significantly lowered toxicity and ulcerogenic activity. Recently, the metabolism of endocannabinoids by COX-2 was suggested to be differentially regulated by NSAIDs. We analysed the affinity of oleamide, arachidonamide and stearoylamide at the FAAH-1 in vitro and investigated the potency of selected NSAIDs on the hydrolysis of endocannabinoid-like molecules (oleamide, arachidonamide and stearoylamide) by FAAH-1 from rat liver. NSAIDs were initially screened at 500 μM after which those that exhibited greater potency were further analysed over a range of inhibitor concentrations. The substrate affinity of FAAH-1 obtained, increased in a rank order of oleamide < arachidonamide < stearoylamide with resultant Vmax values in a rank order of arachidonamide > oleamide > stearoylamide. The selected NSAIDs caused a concentration-dependent inhibition of FAAH-1 activity with sulindac, carprofen and meclofenamate exhibiting the greatest potency. Michaelis-Menten analysis suggested the mode of inhibition of FAAH-1 hydrolysis of both oleamide and arachidonamide by meclofenamate and indomethacin to be non-competitive in nature. Our data therefore suggest potential for study of these compounds as combined FAAH-1-COX inhibitors.
- 4 January 2022
- Published by Springer Nature in BMC Pharmacology and Toxicology
- Vol. 23 (1) , 1-11
Open AccessAssessment of NSAIDs as potential inhibitors of the fatty acid amide hydrolase I (FAAH-1) using three different primary fatty acid amide substrates in vitro
Pain relief remains a major subject of inadequately met need of patients. Therapeutic agents designed to treat pain and inflammation so far have low to moderate efficiencies with significant untoward side effects. FAAH-1 has been proposed as a promising target for the discovery of drugs to treat pain and inflammation without significant adverse effects. FAAH-1 is the primary enzyme accountable for the degradation of AEA and related fatty acid amides. Studies have revealed that the simultaneous inhibition of COX and FAAH-1 activities produce greater pharmacological efficiency with significantly lowered toxicity and ulcerogenic activity. Recently, the metabolism of endocannabinoids by COX-2 was suggested to be differentially regulated by NSAIDs. We analysed the affinity of oleamide, arachidonamide and stearoylamide at the FAAH-1 in vitro and investigated the potency of selected NSAIDs on the hydrolysis of endocannabinoid-like molecules (oleamide, arachidonamide and stearoylamide) by FAAH-1 from rat liver. NSAIDs were initially screened at 500 μM after which those that exhibited greater potency were further analysed over a range of inhibitor concentrations. The substrate affinity of FAAH-1 obtained, increased in a rank order of oleamide < arachidonamide < stearoylamide with resultant Vmax values in a rank order of arachidonamide > oleamide > stearoylamide. The selected NSAIDs caused a concentration-dependent inhibition of FAAH-1 activity with sulindac, carprofen and meclofenamate exhibiting the greatest potency. Michaelis-Menten analysis suggested the mode of inhibition of FAAH-1 hydrolysis of both oleamide and arachidonamide by meclofenamate and indomethacin to be non-competitive in nature. Our data therefore suggest potential for study of these compounds as combined FAAH-1-COX inhibitors.